Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Radcliffe Department of Medicine's Professor Shoumo Bhattacharya has been working with a UK-based biotechnology firm to find out if his research on the ‘pharmacological goldmine’ in tick saliva might offer a treatment option for COVID-10 patients.

Close up photo of adult female deer tick crawling on a piece of straw

Professor Bhattacharya’s work has found that tick saliva could potentially yield many new drugs which could treat disorders ranging from cardiovascular diseases and stroke to arthritis. His research group has identified a group of tick saliva proteins called evasins, which bind to and neutralise chemokines, a group of chemicals key to causing inflammation in the body.

The researchers also worked out the structural trick that enables tick evasins to block a complex pathway that has multiple routes to the same response. What’s more, they can manipulate this structure to make new, custom-made proteins, producing developed triple headed evasins – essentially combining three different types of evasins to maximise the absorption of chemokine messengers responsible for inflammation in the lungs and circulatory system.

Read more on the Radcliffe Department of Medicine website

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.